Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 1000 iu - injection, powder for - excipient ingredients: sodium chloride; histidine; hydrochloric acid; sucrose; polysorbate 80; calcium chloride dihydrate - the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 500 iu - injection, powder for - excipient ingredients: histidine; calcium chloride dihydrate; polysorbate 80; sucrose; sodium chloride; hydrochloric acid - the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - moroctocog alfa, quantity: 250 iu - injection, powder for - excipient ingredients: polysorbate 80; sodium chloride; hydrochloric acid; histidine; sucrose; calcium chloride dihydrate - the control and prevention of haemorrhagic episodes in patients with haemophilia a, including control and prevention of bleeding in surgical settings. xyntha does not contain von willebrand factor and should not be used by patients with von willebrand's disease.

USA - engelsk - NLM (National Library of Medicine)

emd serono, inc. - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - choriogonadotropin alfa 250 ug in 0.5 ml - ovidrel® prefilled syringe (choriogonadotropin alfa injection) is indicated for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an assisted reproductive technology (art) program such as in vitro fertilization and embryo transfer. ovidrel® prefilled syringe is also indicated for the induction of ovulation (oi) and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure. - before treatment with gonadotropins is instituted, a thorough gynecologic and endocrinologic evaluation must be performed. this should include an assessment of pelvic anatomy. patients with tubal obstruction should receive ovidrel® prefilled syringe only if enrolled in an in vitro fertilization program. - primary ovarian failure should be excluded by the determination of gonadotropin levels. - appropriate evaluation should be performed to exclude pregnancy. - patients in later reproductive life have a greater predisposition to endometrial carcinoma as well as a higher incidence of anovulatory disorders. a thorough diagnostic evaluation should always be performed in patients who demonstrate abnormal uterine bleeding or other signs of endometrial abnormalities before starting fsh and ovidrel® prefilled syringe therapy. - evaluation of the partner's fertility potential should be included in the initial evaluation. ovidrel® prefilled syringe (choriogonadotropin alfa injection) is contraindicated in women who exhibit: - prior hypersensitivity to hcg preparations or one of their excipients. - primary ovarian failure. - uncontrolled thyroid or adrenal dysfunction. - an uncontrolled organic intracranial lesion such as a pituitary tumor. - abnormal uterine bleeding of undetermined origin (see "selection of patients" ). - ovarian cyst or enlargement of undetermined origin (see "selection of patients" ). - sex hormone dependent tumors of the reproductive tract and accessory organs. - pregnancy.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

bayer australia ltd - octocog alfa, quantity: 2000 iu - injection, diluent for - excipient ingredients: water for injections - kogenate fs is indicated for the treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency). it may also be used in patients with factor viii inhibitors (neutralising antibodies) who continue to respond to infused factor viii. kogenate fs does not contain von willebrand factor and hence is not indicated in von willebrands disease.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - follitropin alfa, quantity: 150 iu; lutropin alfa, quantity: 75 iu - injection, powder for - excipient ingredients: sucrose; dibasic sodium phosphate dihydrate; monobasic sodium phosphate monohydrate; methionine; polysorbate 20; phosphoric acid; sodium hydroxide - pergoveris is indicated for the stimulation of follicular development in women with severe lh and fsh deficiency.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 3000 iu - injection, diluent for - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrands disease.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

takeda pharmaceuticals australia pty ltd - octocog alfa, quantity: 2000 iu - injection, diluent for - excipient ingredients: water for injections - advate is indicated for use in haemophilia a for prevention and control of haemorrhagic episodes. patients with haemophilia a may be treated with advate as perioperative management. advate is not indicated in von willebrand's disease.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

janssen-cilag pty ltd - epoetin alfa, quantity: 40000 iu/ml - injection, solution - excipient ingredients: glycine; polysorbate 80; monobasic sodium phosphate; water for injections; dibasic sodium phosphate dihydrate; sodium chloride - eprex is indicated for the treatment of patients with symptomatic or transfusion requiring anaemia associated with chronic renal failure to improve their quality of life by improving energy levels, exercise performance, fatigue and sleep patterns and by reducing the need for blood transfusions. eprex is also indicated for the prevention and treatment of anaemia in adult patients with non-myeloid malignancies, where anaemia is anticipated to develop and develops as a result of concomitantly administered chemotherapy. eprex is indicated to decrease the need for transfusion in patients who will continue to receive concomitant chemotherapy for a minimum of two months. eprex is also indicated in adult patients with mild-to-moderate anaemia (haemoglobin >10 <=13 g/dl) scheduled for elective surgery with an expected moderate blood loss (2-4 units to 900 to 1800ml) to reduce exposure to allogenic blood transfusion and to facilitate erythropoietic recovery. eprex is also indicated to augment autologous blood collection and to limit the decline in haemoglobin in anaemic adults patients who are scheduled for major elective surgery and who are not expected to predeposit their complete perioperative blood needs.

Australien - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - nonacog alfa, quantity: 2000 iu - injection, powder for - excipient ingredients: glycine; sucrose; polysorbate 80; histidine - benefix is indicated for the control and prevention of haemorrhagic episodes in patients with haemophilia b (congenital factor ix deficiency or christmas disease), including control and prevention of bleeding in surgical settings. benefix is not indicated for the treatment of other factor deficiencies (e.g. factors ii, vii and x), nor for the treatment of haemophilia a patients with inhibitors to factor viii, nor for the reversal of coumarin induced anti-coagulation, nor for the treatment of bleeding due to low levels of liver-dependent coagulation factors.